Axial spondyloarthritis: a current look at the concept and evolution of the disease

Rumyantseva, D. G.; Эрдес, Ш. Ф.

doi:10.14412/1996-7012-2019-4-4-10

Cited by 10 publications

(5 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Спондилоартриты -группа хронических воспалительных заболеваний позвоночника, суставов, энтезисов, характеризующаяся общими клиническими, инструментальными и генетическими особенностями. К ним относятся анкилозирующий спондилит (АС), псориатический артрит (ПсА), спондилоартриты, ассоциированные с воспалительными заболеваниями кишечника (ВЗК), реактивный артрит (РеА), а также недифференцированный СпА [1,2].…”

Section: Introductionunclassified

Enthesopathy in spondyloarthritis: the literature review

Абдулганиева

Kirillova

Файрушина

et al. 2021

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Section: Introductionunclassified

Enthesopathy in spondyloarthritis: the literature review

Абдулганиева

Kirillova

Файрушина

et al. 2021

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

“…Н.И. Пирогова Санкт-Петербург; 19 ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России, Новосибирск; 20 ГБУЗ Челябинской области «Челябинская областная клиническая больница», Челябинск; 21 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.…”

unclassified

“…Мы рассчитываем, что проспективный этап исследования позволит более детально изучить и понять как позитивные, так и негативные стороны стратегий диагностики аксСпА в реальной клинической практике в Российской Федерации. Но уже сегодня можно констатировать, что ситуация с обращением к врачам по поводу ХБС, а также с назначением рент- При сравнении исходных характеристик пациентов с нр-аксСпА, наблюдавшихся в настоящей работе и в других когортных исследованиях [21], не выявлено существенных различий в основных клинических проявлениях. Как и в предыдущих работах, среди больных с нр-аксСпА преобладали женщины.…”

unclassified

Results of a non-interventional multicenter study of management of patients with non-radiological axial spondyloarthritis in real-life clinical practice in the Russian Federation (NiSpAR)

Dubinina,

Lila,

Kvasova

et al. 2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

NiSpAR is a non-interventional, multicenter study whose aim was to describe a cohort of patients with non-radiological axial spondyloarthritis (nr-axSpA) and approaches to its diagnosis in the Russian Federation.Material and methods. The study involved 20 research centers in different regions of the Russian Federation. The work consisted of two phases: retrospective data collection 12 months before enrolment in the study and prospective observation of patients in whom the diagnosis of nr-axSpA was confirmed (104 weeks).The study included 272 patients who met the inclusion and exclusion criteria (Full Analysis Set, FAS). The mean age of the FAS-population was 38.7±11.0 years. The diagnosis of nr-axSpA was confirmed in 159 (58.5 %) of the 272 patients. Of the remaining 113 (41.5%) participants, 57 (50.4%) did not have the information required to confirm the diagnosis, 34 (30.1%) did not have pelvic radiographs, and 22 (19.5%) did not fulfil the ASAS criteria for nr-axSpA.Results and discussion. The mean age of patients with nr-axSpA was 37.6±10.4 years, more than half of them (52.8%) were women. The median disease duration was 36 [12; 80] months. In half of the patients the disease duration was more than 2 years, in more than one third – less than 2 years. The median CRP and ESR values were 5.0 [2.0; 12.0] mg/l and 11.0 [5.0; 18.0] mm/h, respectively. The BASDAI averaged 3.5±2.0 and was >4 in more than half of the cases (64.2%). The mean ASDAS-CRP value reached 2.6±1.1. Only 1 in 5 participants (20.8%) had low axSpA activity, while in 61.1% it was high (44.7%) or very high (16.4%). An inactive state was found in a small number of patients (9.4%). Twenty two (13.8%) patients had treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) in anamnesis, and 21 (13.2%) patients were still taking them.Conclusion. The results of the retrospective phase of the study show that in real-life clinical practice in the Russian Federation there is a continued positive trend towards improving the diagnosis of nr-axSpA. The median duration of the disease at the time of enrolment in the study was 3 years. The frequency of use of magnetic resonance imaging has increased by more than 1.8 times. At the same time, practitioners still have difficulties in establishing the diagnosis of nr-axSpA and a shortage of bDMARDs for treatment of these patients.

show abstract

“…Аксиальный спондилоартрит (аксСпА) -заболевание из группы спондилоартритов, которое характеризуется хроническим воспалительным поражением осевого скелета, а также внескелетными и внеаксиальными проявлениями [1,2]. АксСпА чаще всего манифестирует в молодом трудоспособном возрасте и в отсутствие эффективного подавления иммуновоспалительного процесса приводит к функциональным и структурным нарушениям, существенно ухудшающим качество жизни, развитию коморбидности и осложнений со стороны различных органов и тканей, что определяет медико-социальную значимость данной патологии [3].…”

unclassified

Comparative analysis of the efficacy of seniprutug (BCD-180) and adalimumab in the treatment of active radiographic axial spondyloarthritis: results of a systematic review and matching-adjusted indirect comparison

Lila,

Dubinina,

Tolkacheva

et al. 2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Objective: to compare the clinical efficacy of seniprutug (BCD-180) and adalimumab (ADA) in the treatment of adults with active radiographic axial spondyloarthritis (r-axSpA).Materials and methods. Based on the results of a previously conducted systematic review, an unanchored matching-adjusted indirect comparison (MAIC) was performed, adjusting for confounding factors. The analysis was based on the results of randomized placebo-controlled clinical trials of seniprutug (BCD-180-2/ELEFTA, NCT05445076) and ADA (ATLAS, NCT00085644) that met the selection criteria. We chose ASAS40 and ASAS20 measurements at week 24 as efficacy outcomes. Initial BASDAI and BASFI indices, proportion of women in the study population, time from disease onset, and baseline C-reactive protein (CRP) levels were considered as confounders.Results and discussion. The MAIC showed a statistically significant advantage in the clinical efficacy of seniprutug (BCD-180) over ADA. When adjusted, the odds ratios (OR) with 95% confidence intervals (CI) for seniprutug (BCD-180)/ADA were 1.86 (1.15; 3.02) and 2.21 (1.34; 3.72) for ASAS40 and ASAS20, respectively, at week 24.Conclusion. The MAIC demonstrated statistically significant superiority of seniprutug (BCD-180) over ADA on the key efficacy endpoints ASAS40 and ASAS20 at week 24 in adults with active r-axSpA. The inclusion of the innovative domestic drug seniprutug into treatment paradigm of active r-axSpA will potentially reduce the socio-economic burden of this disease by providing an affordable, effective and safe therapy while optimizing healthcare costs

show abstract

Axial spondyloarthritis: a current look at the concept and evolution of the disease

Cited by 10 publications

References 60 publications

Enthesopathy in spondyloarthritis: the literature review

Enthesopathy in spondyloarthritis: the literature review

Results of a non-interventional multicenter study of management of patients with non-radiological axial spondyloarthritis in real-life clinical practice in the Russian Federation (NiSpAR)

Comparative analysis of the efficacy of seniprutug (BCD-180) and adalimumab in the treatment of active radiographic axial spondyloarthritis: results of a systematic review and matching-adjusted indirect comparison

Contact Info

Product

Resources

About